D-Index & Metrics Best Publications

Massimo Cristofanilli

Cornell University
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 104 Citations 51,874 793 World Ranking 4104 National Ranking 2322

Overview

What is he best known for?

The fields of study Massimo Cristofanilli is best known for:

Cancer
Breast cancer
Chemotherapy

Circulating tumor cell and Primary tumor are the two main areas of interest in his Metastasis studies. By researching both Oncology and Radiation therapy, Massimo Cristofanilli produces research that crosses academic boundaries. Massimo Cristofanilli carries out multidisciplinary research, doing studies in Radiation therapy and Breast cancer. While working on this project, he studies both Breast cancer and Targeted therapy. His study brings together the fields of Multivariate analysis and Internal medicine. He performs integrative Cancer and Disease research in his work. He performs integrative study on Disease and Cancer in his works. His work in Metastatic breast cancer is not limited to one particular discipline; it also encompasses Palbociclib. His Retrospective cohort study study frequently links to related topics such as Surgery.

His most cited work include:

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment (393 citations)
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system (186 citations)
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer (133 citations)

What are the main themes of his work throughout his whole career to date

A majority of his Fulvestrant research is a blend of other scientific areas, such as Palbociclib and Estrogen receptor. In his research, he undertakes multidisciplinary study on Estrogen receptor and Fulvestrant. Internal medicine is closely attributed to Confidence interval in his study. Massimo Cristofanilli performs multidisciplinary study in the fields of Confidence interval and Hazard ratio via his papers. Massimo Cristofanilli performs multidisciplinary studies into Cancer and Tamoxifen in his work. He performs multidisciplinary study in the fields of Oncology and Gynecology via his papers. In his research, he performs multidisciplinary study on Gynecology and Oncology. Massimo Cristofanilli integrates several fields in his works, including Breast cancer and Cancer research. Cancer research and Metastasis are two areas of study in which Massimo Cristofanilli engages in interdisciplinary work.

Massimo Cristofanilli most often published in these fields:

Internal medicine (95.45%)
Cancer (95.45%)
Oncology (93.18%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis;Alison Stopeck.
The New England Journal of Medicine (2004)

4874 Citations

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André.
Journal of Clinical Oncology (2008)

3088 Citations

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim.
Clinical Cancer Research (2005)

2386 Citations

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser.
Journal of Clinical Oncology (2005)

1609 Citations

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro.
Lancet Oncology (2016)

1516 Citations

Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

Sabine Riethdorf;Herbert Fritsche;Volkmar Müller;Thomas Rau.
Clinical Cancer Research (2007)

1435 Citations

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)

1413 Citations

Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis.
Journal of Clinical Oncology (2005)

1284 Citations

Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

Daniel F. Hayes;Massimo Cristofanilli;G. Thomas Budd;Matthew J. Ellis.
Clinical Cancer Research (2006)

1132 Citations

Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

G. Thomas Budd;Massimo Cristofanilli;Mathew J. Ellis;Allison Stopeck.
Clinical Cancer Research (2006)

908 Citations

If you think any of the details on this page are incorrect, let us know.